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Principles of Transplantation 
Jorge Reyes, Thomas E. Starzl 
Assuming the availability of a good intensive care unit and ef-
fective outpatient care, successful transplantation of any whole 
organ rests on five specific laboratory-based principles: surgical 
technique; preservation technology; considerations of histocom-
patibllity; immunosuppression; and, least appreciated, the inci-
dental induction of varying degrees of donor-specific nonreac-
tivity (tolerance), without which none of our organ recipients 
could be rehabilitated for long. Traditionally, the last three of 
these considerations have been discussed separately. However, 
the discovery in 1992 that all patients bearing long surviving or-
gan allografts had donor leukocyte chimerism8o•81 and the real-
ization that this must be accomplished for successful xenotrans-
plantation96 has made such a reductionist approach obsolete. 
Consequently, the first section of this chapter will describe the 
interrelation of his to. compatibility, immunosuppression, and tol-
erance. The last cwo sections will briefly discuss organ preserva-
tion and the limitations of clinical tissue matching. Expositions 
of surgical technique can be found in organ-specific chapters. 
THE IMMUNOLOGIC BARRIER 
The modern evolution of clinical transplantation of whole or-
gans has spanned 40 years. This evolution has involved some of 
the most remarkable and conceptually enigmatic developments 
in the hiscory of medicine. Successful engraftment of the kid-
ney,50 liver,84 hearc,9 lung,23 pancreas,36 intestine,31 and multi-
ple abdominal viscera94 was a cumulative achievement. largely 
accomplished by dogged trial and error. Each organ-defined spe-
cialty has had historians who track their story back to one of 
the foregoing milescones where the trail goes cold. The reason 
is that such accounts are preoccupied with a succession of events 
rather than the biologic principles that apply to all organ aIlo-
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grafts. This was understandable because there was no rational 
reason co expect that a transplanted histoincompatible organ 
could breach the seemingly inviolate barrier of immunologic re-
activity using the treatment formulas that became standard. 
When this proved feasible. the inability to explain why caused 
an ever-increasing number of clinical transplant surgeons and 
physicians to regard basic immunology as an interesting hobby, 
irrelevant to their practice. 
The Beguiling Identical Twins 
The potential benefit of whole organ replacement in the absence 
of an immune barrier was dramatically demonstrated with the 
identical cwin kidney transplantation performed in December 
1954 by Murray49 (Nobel Laureate, 1990). Although symboli-
cally important, this achievement only confirmed what already 
was known to be possible with identical cwin skin grafts.49 Seven 
years later, the Nobel Laureate (1960), Burnet l6 reported in The 
New EnglAnd Journal of Medicine that" ... much thought has 
been given to ways by which tissues or organs not genetically 
and antigenetically identical with the patient might be made to 
survive and function in the alien environment. On the whole, 
the present oudook is highly unfavorable to success .... n 
The One-Way Paradigm 
Rejection 
What was the genetically determined barrier? AJthough it has 
never been precisely defined, there was little mystery after 1944 
about the general meaning of rejection after its elucidation by 
Medawar~S (co-Nobel Laureate with Burnet, (960) as an im-
munologic event. This great contribution created the indelible 
image that a tissue (or organ) allograft was an island in a hos-
tile recipient sea (Fig. 35-1, A). 
Tolerance 
In contrast, why allografts or xenografts could escape from re-
jection without crippling the recipient with immunosuppression 
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Chapter 3S Pri nciplcs (If Transplantation 549 
was one of the great mysteries of biology for nearly 40 years af-
ter the description of acquired tolerance by Billingham et al. l .I . 11 
[n their experimental model. immunocompetent adult spleen 
cells were injected in utero or perinatally into mice that were 
not yet immunologically able to reject them. The engrafted cells 
flourished and in effect endowed the recipient with the donor 
immune system (leukocyte chimerism) (Fig. 35-1. 11). 
Thereafter. the mice failed to recognize donor strain skin 
grafts or other tissues as alien (a concept known as acquired tol-
erance). The switch in immunologic apparacus was consistenc 
with the definition of transplantation immunology in terms of 
a unidirectional immune reaction (the "one-way paradigm"). 
Main and Prehn"o demonstrated the same tolerance outcome as 
Billingham et al 13· '4 in irradiated adult mice, whose cytoablated 
hematolymphopoietic cells were reconstituted with bone mar-
row instead of spleen cells. Hundreds of subsequent tolerance 
induction experiments in animals and eventually clinical bone 
marrow transplantation seemingly depended upon a similar nat-
ural. or iatrogenically imposed. defenseless recipient state (see 
Fig. 35-1. B). 
Graft-versus-host disease 
[t was recognized as early as 1957 in mouse l2 and chicken mod-
els70 that an immunologically active graft could turn the tables 
and reject the recipient. using a complete genetically controlled 
repertoire of immune reactivity similar to that of the recipient. 
This was called graft-versus-host disease (GVHD). or alterna-
tively "runt disease". If the host was immunologically defense-
less. the risk for this disease was approximately proportional to 
the extent of the major histocompatibility complex (MHC) dif-
ference between donor and recipient. Such disparities became 
measurable serologically in humans after identification of the 
HLA antigens by Dausset21 (Nobel Laureate, 1980), T erasaki, 101 
and others whose reminiscences have recently been collected. 
For many years, the complication of GVHD in rodent llO and 
large animal irradiation chimera models3M I.60.,o5 forestalled the 
clinical use of HLA-mismatched bone marrow cells or other ma-
ture immunocytes both for immunologic reconstitution with 
purely hematologic objectives and as a means of facilitating 
whole organ graft acceptance. 
Clinical bone marrow transplantation 
The strategy that eventually made possible clinical bone mar-
row transplancation in 1968 was a straightfotward extension of 
the rodent experiments with similar histocompatibility-imposed 
restrictionsK~·OKIK44 After recipient cytoablation with total body ir-
radiation or cytotoxic drugs (see Fig. 35-1. 11). stable chimerism 
could be induced in humans by the infusion of donor bone mar-
row if there was a good HLA match. Otherwise. ;111 intolerable 
incidence of lethal GVHD occurred. At varying times after suc-
cessful engraftment. maintenance immunosuppression was fre-
quently not needed. mimicking the kind of acquired immuno-
logic tolerance originally described by Billingham et al l .I . 14 ;\Ild 
then Main and Prehn.'" 
Clinical organ transplantation 
Total body irradiation 
The accomplishment of clinical bone marrow transplantation 
eFfectively detached from a scicmilic baK~e surgeons and physi-
cians who by this time had recorded many successful human 
whole organ transplantations (mosdy kidneys) under cominu-
ous immunosuppression without either dependence on H LA 
matching or the complication of CVHD. Most immunologists 
were dumbfounded by these successes. 
Host preconditioning played a hismrically important role in 
the first six successful renal transplantations (defined as survival 
for more than 1 year) between 1959 and 1962-one in Boston ~Ef 
and five in France .. n .. 1H The recipients were prepared for oper-
ation with sublethal mtal body irradiation but without donor 
bone marrow. Theil 0wn bone marrow recovered, and one of 
these patients (in Paris) survived for 26 years; however. these 
were isolated successes in a sea of failures. and pessimism set in 
worldwide about the prospects of moving forward. 
Chemical immunosuppression 
The frustration continued after the introduction for human re-
nal transplantation of 6-mercaptopurine (6-MP) and its ana-
logue. azathioprine. following extensive experimental studies. 
first with rodent skin transplantation47 .68 and then with canine 
kidney transplanc models.17.IR.H.IIH The drugs were originally 
developed as antileukemic agents by Elion and Hirchings2; 
(Nobel Laureates. 1988) and were first demonstrated to be im-
munosuppressive by Schwartz and Dameshek.67 Although the 
sixth patient treated by Murray with one or the other of these 
myelotoxic drugs had function in a non-related renal allograft 
for 17 months. the clinical results were poor at flrst.H. H simi-
lar to those with total-body irradiation (TBI). 
The drug cocktail breakthrough 
When azathioprine was combined with prednisone in 
1962-63.90 the tidal wave of whole organ cases began in earnest. 
A characteristic cycle of convalescence was identified in which 
kidney rejection could be reversed surprisingly easily with pred-
nisone. More important, the later need for maintenance im-
munosuppression frequently declined as if the immune barrier had 
been lowered (Fig. 35-2); and in occasional cases therapy could 
be stopped. The same sequence has been seen since with all other 
org.ms transplanted and with all of the two-drug and more com-
plex multiple agent immunosuppressive regimens. Drugs intro-
duced later were more potent and reli;\ble in chaperoning the de-
sired chain of events: antilymphocyte globulin (ALG).II" 
cyclosporine. I" and FK RMS:F~ Notwidmanding their diversity. all 
seemed in a fundamentally simil;lr way to have allowed something 
to ch;lIIge in the host, the graft or both. But what? 
Answers were nor provided by the one-way paradigm. 
Nevertheless. the false conception of a unidirectional reaction 
W;\s reinforced with the introduction in 1963 of ,he one-w;\y 
mixed lymphocyte reaction.v These and other in vitro tech-
niques (the so-called minitransplant models) generated thousands 
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Figure 35-2 P:mern of poslOl'n:lliw 
evcllls with whole orgall allogr:lft 
accqH:1IlCe in the framcwork of the 
one-w;IY paradigm. 
Immune 
Reaction 
o 
of increasingly sophisticated cellular and ultimately molecular 
studies of unidirectional immunologic reactions. The resulting 
plethora of new information resembled at times the entries in an 
exponentially expanding phone book. Most seriously, the flawed 
context lured successive generations of investigators into the trap 
of believing that tolerance induction for whole organ recipients 
(the "holy grail") lay in variations on the HLA-limiting strategy 
that was used for bone marrow transplantation. This strategy in-
cluded host preconditioning in preparation for various donor 
leukocyte preparations. 
Cell-mediated immunity 
By the early 1970s, most virologists and basic immunologists 
who were attempting to understand organ rejection shifted their 
efforts from whole animal studies to the T Iymphocyte-oriented 
cell culture (i.e., in vitro) systems. These labors were rewarded 
by a Nobel Prize (Baruj Benacerraf. 1980) and the Lasker Prize 
in Basic Science of 1995, which was shared by four Americans 
and one SwiSS.21.112.117 The conceptual model that emerged 
from these srudies provided an explanation of cell-mediated im-
munity (Fig. 35-3). In the context of the one-way paradigm, 
the details of the allogeneic reaction (i.e., rejection) included its 
dependence on antigen-presenting cells, the necessity for a 
costimularory molecule(s) (the two-signal concept of self/non-
self-discrimination), the important role of accessoty molecules, 
and cytokine control of clonal expansion of T-helper lympho-
cytes as well as of the cytotoxic T cells that arc the agents of 
allograft destruction. The bewildering mass of details (0 which 
thousands of investigators had contributed over a 3-decade 
period had long since overwhelmed most clinicians interested 
in applying the new information. 
In the meanwhile. rhe surprising diversity had been docu-
mented of agents with which long-term or permanent graft sur-
vival could be indllced with a short course of therapy. regard-
less of the level at which the ;Igent illlervenes in the immune 
reaction I"'. (Fig. 35-3). I>eoxyspergllalin was believed to alter 
Recipient 
.Immune 
Apparatus 
I 
30 
Days after transplantation 
the function of antigen-presenting cells, of which dendritic cells 
were considered to be the most important. The antimetabolite 
drugs prevenred clonal expansion of lymphocytes by inhibition 
of deoxyribonucleic acid (DNA) synthesis. Cyclosporine and 
tacrolimus (FK 506) disrupted signals from T-cell receptor sites 
ro the nucleus. Monoclonal anribodies (MA) inrerrupted the im-
mune reaction at the various specific targets shown in Figure 
35-3, and rapamycin inrerdicted the sequence of events even af-
ter the secretion of the cytokine interleukin 2 (formerly called 
T-cell growth facror). The new immunosuppressive fusion pro-
tein CTLA4-Ig blocks the transmission of a second signal (the 
B7-CD28 pathway). All appeared ro be permissive of a natural 
event that became specific only by virtue of the presence of 
donor antigens. 
The Two-Way Paradigm 
Whole organ transplantation 
Insight into what was happening to the pioneer organ recipi-
ents was obtained in retrospect by studies at the University of 
Pirrsburgh nearly 30 years later of a group of kidney and liver 
recipients who were still extant from the earliest clinical trials at 
the University of Colorado. Donor leukocytes of bone marrow 
origin ("passenger leukocytes"71.?), which are parr of the muc-
ture of all complex grafts, were found to have migrated from 
the organs and survived ubiquitously in the patients for up (0 
3 decades. Ho.HI Thus, organ allograft acceptance was associated 
with the cryptic persistence of a small fragment of extra-
medullary donor marrow, including stem cells (depicted as a 
bone silhouette in Fig. 35-1, C). These cells had been assimi-
lated into the overwhelmingly larger immunologic network of 
the host. The leukocyte movement occurred in both directions. 
with a small number of residual donor leukocytes (microchi-
Illerism) in both the graft and host. 
From this information, a revision of transplantation im-
IIll1nology was possible in which the immunologic confronta-
tion I(lilowing whole organ transplantation could be seen as a 
Chapter 35 Principles of Transplantation 551 
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Figure 35·3 A schematic representation of the antiallograft 
immune response showing the cell-surface proteins that participate in 
antigen recognition and signal transduction, the contribution of . 
cytokines, and the sites of action of the diverse agents that prolong 
graft survival. Antigen (allopeptide) recognition by means of the 
T-cell receptor (TCR) and the role of accessory molecules can be 
blocked by monoclonal antibodies (MA), as can cytokine-re:ceptor 
expression. Deoxyspergualin (D) is belie:ved to inhibit the: function 
of antigen-presenting cells (APC). FK 506 (F) (now tacrolimus) and 
cyclosporine (C) inhibit cytokine: gene expression within T-helper 
(TH) cells, whereas rapamycin (R) blocks the responses of T cells to 
interleukin (IL)2. By inhibiting DNA synthesis, the antimetabolite 
drugs (A) act later than FK 506, cyclosporine, or rapamycin to block 
lymphocyte proliferation. CTLA4-lg (en is a new agent that blocks 
transmission of the: second signal (B7-CD28) pathway that is 
essential for T-cdl activation. (l) and (II): major histocompatibility 
complex (MHC) antigens class I and II, respectively. 
bidirectional and mutually cancelling (gralt-versus-host [GVH] 
as well as host-versus-graft [HVGJ) interaction (Fig. 35-4), pro-
viding the two participants in the David/Goliath mismatch 
could survive the initial confrontation. Clinically, but not in 
several animal models. such survival requires an umbrella ofim-
munosuppression that protects both cell populations equally (see 
Fig. 35-1. C). 
Understanding the amplication device by which a small num-
ber of donor cells can so profoundly affect the immunologic vi-
sion of the vast recipient army against which it is arrayed is of 
intense scientific inreres[. The chimeric leukocytes are multilin-
eage. OOK~ffKff11KffD However. the anrigen-presenting dendritic cells 
(DCs) of Steinman and Cohn')7.')11 are believed [0 be key [0 the 
reciprocal tolerogenic process bec.1use they can modify. in both 
cell populations. the expression of cell inreraction. MHC, and 
adhesion molecules-all of which determine how antigen sig-
nals arc heeded by T cells."? 
Historical enigmas 
With thc two-way paradigm. the reason for virtually every pre-
viously unexplained experimenral or clinical observation after 
whole organ transplantation became either transparent, or at 
least susceptible to experimental inquiry.Hu.H' It could be un-
derstood why organ grafts arc inherendy tolerogenic, why HLA 
matching is so poorly predictive of outcome, and why GVHD 
does not develop after the transplantation of immunologically 
active grafts (such as the liver and intestine) or as it w~ soon 
learned, even of bone marrow providing the recipient im-
munologic system is left intact. 
With the two-way mutual cancellation implicit in this con-
cept, the loss or blunting of an HLA-matching effect is easy (0 
understand. With each further level of histoincompatibiliry. the 
reciprocal effect apparendy escalatcs both ways under the um-
brella of effective immunosuppression (Fig. 35-5). The conse-
quent dwindling of the matching effect as donor-specific and 
recipient-specific nonreactiviry evolves accounts for "blindfold-
ing" of the expected HLA influence. 
In addition to explaining why the HLA matching effect is 
mitigated. the mutual functional cancellation of the two cell 
populations explains why GVHD does not develop after liver, 
intestinal, multivisceral, and heart-lung transplantation. despite 
the he:avy lymphoid content of those organs. 
Augme:ntation of spontaneous chimerism 
Because acquisition of immunologic tOlerance in the Billingham-
Brent-Me:dawar and derivative modc:ls depended on donor 
leukocyte: (splenocyte: or bone marrow) infusion,I3·14.40 sporadic 
anempts have been made to improve organ allograft outcome 
by infusing adjuvant donor bone marrow8.S1 or blood.3•64.72 
These were hampere:d in design or execution by the: assump-
tion that the infused cells would be destroyed unless there were 
recipient preconditioning with irradiation or myelotoxic drugs. 
In rum, the prospect of recipient cytoablation engendered jus-
tifiable anxiery about causing GVHD. The appropriate timing 
of the cell infusions was also controversial. Consequently, this 
strategy never gained a clinical foothold. 
The information that emerged in 1992 indicating that leuko-
cyte chimerism is a naturally occurring event after whole organ 
transplantation8o.81 exposed a perioperative window of oppor-
tunity during which unaltered HLA-incompatible bone marrow 
or donor-specific blood transfusion were predicted to be safe 
without recipient preparation or any deviation from the generic 
noncytoablative practices of immunosuppression for whole or-
gan transplantationrhat had evolved over the years from the 
original prednisone/azathioprine formula.'X) 
The validiry of this strategy was verified recently in nonpre-
conditioned recipients of cadaveric kidneys. livers. hearts. and 
lungs who were given 3 (0 5 X 1M~/kg adjuvant bone marrow 
cells during organ transplantation under standard tacrolimus-
prednisone treatmenr (Fig. PR-SFKl~ Chimerism estimated (0 be 
more rhan 1000 times that which occurs in conventional whole 
552 Part IV Transplantation 
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Figure 35-4 The pattern of 
convalescence after either organ or bone 
marrow transplantation in the 
framework of the [Wo-way paradigm. 
Immune 
Reaction 
Figure 35-5 Explana[ion for the loss of an 
HLA-ma[ching effect with whole organ 
transplanta[ion. Rx-Immunosupprcssion. 
o 
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Figure 35-6 Iaerogenic augmentaeion of ehe graft-versus-hose (GVH) component of ehe cwo-way 
paradigm by infusing 3 co 6 X 108 unalee~ed donor bone marrow cells during whole organ 
transplantation. When ehe recipient is not cycoablated, essentially no risk for GVH disease exists. 
organ recipients was produced and sustained reliably and safely. 
The persistent blood chimerism (usually> 1%), trend toward 
donor specific nonreactiviry, and high rate of patient and graft 
survival has marked these bone marrow-augmented recipients 
as an advantaged cohon. These patients are the first to undergo 
HLA-mismatched cadaveric organ transplantation with the hope 
of eventually becoming drug free. The process of tolerance in-
duction and drug weaning is expected to take 5 to 10 years; and, 
in some the drug free state may never be arrainable. 
The drug-free state 
The concept that organ transplantation is equivalent to a small 
bone marrow transplantation (and that this explains allograft ac-
ceptance) has gone well beyond a hypothesis. The human phe-
nomenology has been confirmed and gready extended in ani-
mal models. principally by Qian et al,s8 Murase et al.52 and 
Demetris et al. 22 The cardinal principle revealed by the clinical 
and animal studies is thae ehe long and continuing survival of 
an organ allograft means by definition that donor leukocyte 
chimerism is present. Failure to demonstrate chimerism in such 
recipients connotes an inadequate search. 52 
Does chis mean chat chimerism is synonymous with toler-
ance? Of course not. Donor leukocyte chimerism is merely a 
prerequisite for graft acceptance.80 Is the demonstration of 
chimerism an indication to Stop immunosuppression? This 
shockingly naive question has been asked of us dozens of times. 
even by experienced clinicians. The answer is "No"! However. 
knowledge of the chimerism mechanism makes it clear why 
drugs can be stopped permanendy after organ transplantation 
In some cases. 
In early 1992, we formally reevaluated 43 liver recipients who 
had received the transplant 10 to 23 years previously.sl More 
than half of the recipients had been infants or children at the 
time of their operation. Five (12%) of the 43 were already off 
drugs at that time, and had been for 1 to 15 years. Since then, 
one of the 43 long survivors died from recurrent hepatitis S, 
leaving 42 survivors in October 1995. During the 3.5 inter-
vening years, seven more of these recipients came off of drugs. 
Thus. the incidence of drug freedom in this bellwether cohon 
of liver recipients, who represent approximately 80% of the 
longest survivors in the world after this procedure. is 12 of 42 
or 28%. The nearly equal cumulative duration of these 12 pa-
tients off of immunosuppression (coded grey) and under treat-
ment (shown in black) is evident in Figure 35-7. 
Complementing the foregoing observations. Ramos et alS9 
have reponed a prospective weaning erial for liver recipients. 
limited for ehe mose pan to paeients who were 5 to 10 years 
pose-transplantation. Freedom from rejection for at least 5 years 
was a prerequisite. Since the first repon, the trial has expanded 
to 80 patients (Fig. 35-8). Forry-four (55%) of these liver re-
cipients have come otT drugs completely or have moved unin-
terruptedly in that direction. In 22 patients whose weaning is 
complete, the drug-free rime averages 2.5 years. Weaning is now 
being done more slowly than at rhe beginning of the trial be-
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Figure 35-7 Time on (black) and off (gray) of immunosuppressive therapy of 12 long-term 
surviving liver transplanl recipients having no drug treatment in October 1995. Patients 150 and 
169 stopped their medication less than 2 years after transplamarion because of noncompliance. The 
OIher 10 were weaned because of complications of chronic immunosuppression. These 12 patients 
represent 28% of the 42 in our cotal experience who have continuously born hepatic allografts for 15 
co 25-5/6 years. 
cause of a 30% incidence of rejection (see Fig. 35-8). It was ev-
idem that most of the 80 liver recipiems had been at a level of 
immunosuppression higher than they needed. 
The foregoing trial did not include cases in which immuno-
suppression was sropped because of life-threatening infections. 
Ten pediatric liver recipients whose drugs were discontinued 
permanently as early as 6 months after transplantation because 
of Epstein-Barr virus (EBV). associated B-cell lymphomas. hu-
man immunodeficiency virus (HIV). or hepatitis C virus are 
listed in Table 35-1.(·2 After an average drug-free period of more 
than 4 years. eight (80%) of these 10 patienrs remain drug free 
and healthy. including 5 of the 6 patiems whose EBV-associ-
ated B cell lymphomas (also called posmansplant Iymphopro-
liferative disorders IPTLDsJ) melted after drugs were sropped. 
The demollstr;uioll that these tumors respond to im-
mUllomodulatioll has been the most reproducible example of 
cancer imrnunosurveillance ever reported c1inically.'J2 
It is more dangerous to attempt weaning after kidney trans-
piamatio/l, and we rarely recommend this. However. five of our 
longest-surviving living related kidney recipients (the first five 
listed in Table 35-2) have heen ofr of all immunosuppression 
for 2 10 30 years. The first ,lIld third patients. who had double 
H I A haploidelHical donors. were nO/lcomplialH. However. the 
other three of the first five were HLA mismatched. They·and 
[he more recently treated patients 6. 7. and 8 had at least four 
of the serious complications of immunosuppression listed in the 
footnote. Only patient 8 (whose transplantation was done in 
1987) had rejection with weaning. This was promptly diagnosed 
and easily reversed. 
Rejection after drug discontinuance 
The benefits of weaning from immunosuppressive therapy for 
organ recipients are obvious. However. it is equally importam 
to recognize that there was a 30% overall risk for rejection in 
the prospective liver trial. Successful weaning was achieved con-
sistently only in patic;nts who were weaned from an azathio-
prine-prednisone regimen or from monotherapy with tacroli-
mus. s·} When weaning failed. rejection was diagnosed 1 to 29 
months after the beginning of weaning (see Fig. 35-8). Rejection 
was classed histopathologically as minimal to mild in 20 of 24 
patients and moderate or severe in the other four. 
Restoration of the previous baseline immunosuppression was 
the only adjustment required in most t.:ases. but the four pa-
tients with moderate or severe rejet.:tion required rescue treat-
ment with tacrolimus; one patient who required rescue treat-
ment became jaundiced with a peak bilirubin of 12 mg%. 
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Weaning Interrupted' 
n = 12 
Off Drugs 29 ± 20 Months 
n = 22 
(27.50%) Figure 35-8 Summary of the first IlO 
livcr recipielHs in a weaning trial at the 
University of Pittsburgh Medical Center. 
Notc that more than half have heen 
completely off of drugs or are on an 
interrupted schedule of drug reduction. 
The rate of weaning has been slowed 
compared with the original protocol 
because of a .)0% i ncidcnce of rejection. 
There have been no patients or graft losses. 
Weaning is interrupted if noncompliance is 
detected or in the presence of intrinsic 
Mean Weaning Duration 
1.5 years 
(30.00% 
Rejection 
n = 24 
. unreliable followup = 4 
physician panic: 3 
biliary tract pathology: 2 
PSC recurrence: 1 
Ongoing Weaning 
n = 22 liver disease. including the reemergence of 
auroimmune disorders. Mean Duration 25 ± 12 Months 
renal failure: 1 
steatohepatitis: 1 
Although no patients or grafts were lost in our rrial, Sandborn 
et aiM encountered rejection in 6 of 12 patients being rapidly 
weaned from cyclosporine-based triple drug therapy only 3 years 
after transplantation; two of the six died. It would be foolhardy 
to ignore such a warning. 
Bone marrow transplantation 
After the discovery that successful whole organ transplantation 
was associated with spontaneous chimerism. it was realized that 
the perceived schism between the bone marrow and whole or-
gan transplantation fields reflected entrenched differences in 
treatment strategy (Fig. 35-9). The mutually censoring im-
munologic limbs were left intact with organ transplantation. 
whereas the recipient limb was deliberately removed (cycoabla-
tion) in preparation for bone marrow grafting procedures. 
Although it had long been assumed thac che entire recipient im-
mune system had been eliminated with successful bone marrow 
transplantation (see Fig. 35-1. BJ. a rrace population of recipi-
ent leukocyces has been detected with sensitive techniques in the 
blood of almost all such patients. 57. 1 14 These bone marrow re-
cipients were in fact mirror images of those successfully bearing 
whole organ allografts. the difference being chat their own racher 
chan donor leukocytes constituted the trace population. Under 
both circumstances. other such findings as the appearance of 
veco and suppressor cells. enhancing antibodies. and changes in 
cycokine profile could be construed as by-products of and ac-
cessory co the seminal event of the mutual cell engagement (see 
Fig. 35-\' C and D). 
ORGAN PRESERVATION 
Procurement 
The breakthroughs of the early 1960s rim made transplanta-
tion clinically practical were so unexpected that almost no for-
mal preparation had been made to preserve the transplanted or-
gans. Cardiac surgeons had used hypothermia for open-heart 
Table 35-1 Outcome of Therapy Cessation in Pediatric 
Transplant Recipients with Infections* 
PTLO HIV HCV 
n 6 2 2 
Time drugs stopped Median 1 year 6.7 yr 0.5.2 yr 
after [ransplaocation (0.8 to 8 yrs.) 
Survival 5/6 112 2/2 
Time drug free (yrs) 4.1 6.1 4.2 
·A follow-up done until OCtober 1995 of, series reported [0 Ihe American Socie(V of 
Transpl,nl Surgeons in M,y 1993 (64). 
HCV-Hep'lie C virus; HIV-Human immunodeficiency virus; PTLD-
POSllranspianl Iymphoprolife"nive disorders. 
operations from 1950 onward and knew that ischemic damage 
below the level of aortic cross-clamping could be reduced by 
cooling the subdiaphagmatic organs. 55 [n an early report. 
Lillehei et a139 immersed intestines in iced saline before auto-
transplantation. In Boscon. Sicular and Moore69 reported greatly 
slowed enzyme degradation in cold slices of liver. 
Despite this awareness. kidneys from identical twins were 
routinely transplanted with no protection from warm ischemia 
during organ transfer. Until 1963. the only attempt to cool kid-
ney allografts was by the potentially dangerous practice used by 
cardiac surgeons of immersing the living volunteer donor in a 
bathtub of ice water (rotal body hyporhermia).79 This cumber-
some method of cooling was quickly replaced by infusion of 
chilled solutions into the renal artery after donor nephrectomy.7.1 
exploiting a principle of core (transvascular) cooling that had 
been standardized several years earlier for experimental liver 
transplantation. K6 
Core cooling in silll. which is currently the first critical step 
in the preservation of all cadaveric whole organs. is done with 
variations of the technique described in 1963 by Marchioro et 
al4l and was lIsed clinically long before the acceptance of brain 
death criteria which now permits ill Jim cooling to be under-
taken T~ (Fig. 35-10). Ackerman and Snell l and Merkel et al~h 
popularized in Silll cooling of cadavc:ric kidneys with simple in-
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Table 35-2 Weaning of Immunosuppression in Long-Term Living Related Kidney Transplantation 
'.' 
.12 
.12 
.\2 
n 
29 
17 
8 
·C"·;lIinin< 1.0 - .104 - 1.2 mg% (alier rerurn 10 CyAlPrcd). 
tChildrcn ;11 du' lil11l.· nf rransplallt;ttiun. 
0 nc 
I comp 
() nc 
2 comp 
comp 
comp 
comp 
comp 
Comp--Cnmplications of skin can,,,,r. wans. in(('erion. hypcncn~ionK obEIKD~myK or1hopedic problems: nc-Noncomplianl. 
Solid Organ Bone Marrow 
Non-essential ...... :--KKKK:;K-fiKK:KKKKII~--- Tissue Match _----: ..... K:KK:KK111;I;:;K_~- E sse nt i a I 
Acceptance Graft Take ----~KiKijl~-~ Tole r anc e 
Uncommon GVHD Common 
(Medawar) 
Figure 35-9 The growrh as separare disciplines of bone marrow (right) and whole organ 
rransplanrarion E/~ftF from rhe seed planrcd by Pctcr Mcdawar during World War II. Ir was 
recognized in 1992 Ihal rhese seemingly disparate disciplines werc mirror images caused by differenr 
m:armenr su:uegics. GVHD-Grafr-versus-hos[ disease. 
fusion of cold electrolyte solutions into the donor femoral artery 
or distal aorta. Procurement techniques were eventually per-
fected and allowed removal of all thoracic and abdominal or-
gans. induding the liver. without jeopardizing any of the indi-
vidual organs (Fig. 35- t tFKe~ Modifications of this flexible 
procedure have been made for unstable donors and even for 
donors whose heans have s£Opped beating.'JI During the 5 years 
berween 1980 and 1985. such techniques had become inter-
changeable in all pans of the world. setting the stage for reli-
able organ sharing. After the chilled organs are removed. sub-
sequent preservation is possible with pro£Orype strategies: simple 
refrigeration or continuous perfusion (see below). 
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Pump 
Figure 35-11 Principle: of in sim cooling used for multiple orgiln 
procuremem. Wirh limited preliminary dissection of the ilorta ilnd of 
the great splanchnic veins (in this case the splenic vein). cold 
infusares can be used to chill org.lIls in situ. 1 n this case. {he kidneys 
and liver were being removed. Note the aonie cross-ebmp above the 
celiac axis. (From Stanl TE er al: A tlexible procedure for l1lulriple 
cadaveric organ procuremem. Surg Gy"teol ObsU'f 1'i8:22J, 1984. 
Modified with permission.) 
Figure 35-10 First tcchniquc of 
in situ cooling by cxtracorporcal 
hypothcrmic perfusion. The catheters 
wcrc inserted into the aorta and vena 
Glva by way of the femoral vcssels 
as soon as possible after death. 
Tempcrature control was provided 
with a heat exchanger. Cross-clamping 
of the thoracic aorta lim ired perfusion 
to the lower part of the body. This 
method of cadaveric organ procurement 
was used from 1962 to 1969. before 
the acceptance of brain death criteria. 
The preliminary stages of this approach 
provided the basis for subsequent in 
situ infusion techniques. (From Stanl 
TE: Exptrit'nu in rt'nal transplantation. 
1 n Tht rok of cadavtric donors in 
homotransplantation. Philadelphia, 1964, 
WB Saunders.) 
Extended Preservation 
Continuous vascular perfusion 
In rhe first clinical applicarion of continuous vascular perfusion. 
Marchioro et aI42 used a convenrional hearr-Iung machine and 
heat exchanger to continuously perfuse and cool all major or-
gans (see Fig. 35-10). Efforts to continuously perfuse isolated 
organs proved to be more difficult. For renal allografts. 
Ackerman and Barnard I used a normothermic perfusate primed 
with blood and oxygenated wirhin a hyperbaric oxygen cham-
ber. The perfusate was directed into the renal artery. Brett-
schneider et al l5 modified the appararus and were able ro pre-
serve canine livers for 2 days. an unprecedented feat ar the rime. 
When Belzer er allo eliminated rhe hemoglobin and hyperbaric 
chamber components. their asanguinous hyporhermic perfusion 
rechnique was immediarely accepred for clinical renal rrans-
plantar ion bur rhen slowly abandoned in mosr cenrers when ir 
was learned rhar rhe quality of 2-day preservation was not 
markedly better than thar of simpler and cheaper infusion and 
slush methods (see below). However. refinement of perfusion 
techniques may someday permit true organ banking. 
Static preservation 
With rhese "slush techniques." sp~cial solutions. such as thar de-
scribed by Collins er al. 20 or plasmalike solurions(,(' were insrilled 
into rhe renal vascular sysrem of kidneys or (he vascular sysrem 
of orher organs after their preliminary chilling and separation. 
The original Collins solurion. or moditications of ir were used 
for nearly 2 decades before th~y were replaced wirh rhe 
Universiry of Wisconsin (UW) solurion rita[ was developed by 
rhe ream of Folker( Belzer. Althuugh ir was tirsr used for rhe 
liver.II.\\,lIl'1 {he UW solution provides superior preservation of 
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kidneys"'''' 111 ami other organs. The UW pre$ervation per-
mined longer and safcr preservation of kidneys (2 days) and liv-
ers (1 ,by). a higher rate of graft survival. ;lIld a lower rate of 
primary nonfunetion. With the UW solurion, national organ 
sharing was m;lde economical and practical. 
TISSUE TYPING 
Antigen Matching 
The fIrst prospective antigen matching rrials were begun in 1964 
hy Terasaki 1<,. in collaboration with the University of Colorado 
kidney transplantation team. Although the value of this sero-
logic technology was demonstrable when the kidney donor was 
a highly compatible family member (the perfect match),?3 lesser 
degrees of matching correlated poorly with renal tramplamation 
outcome.· The reason for this paradox were inexplicable until 
the discovery of recipient chimerism. Ironically, the belief that 
matching should be a prime determinant of success resulted in 
its use as an overriding factor for the allocation of cadaver kid-
neys in the United States. 
The propriety of this kidney allocation policy has been re-
peatedly challenged on ethical as well as sciemific grounds for 
a quarrel' of a century. Those in favor of its perpetuation cite 
multicenter case compilations in the United States and Europe 
showing a small gain in allograft survival with histocompatible 
kidneys, whereas many of the individual contributing cemers 
see no such trend in their own experience.27.43,63,100 In a com-
pelling recent study, Terasaki et al ,02 reported that early survival 
and the subsequent half-life of kidneys from randomly matched 
living unrelated donors was identical to that of parent-offspring 
(one haplotype matched) grafts. 
In addition ro this hammerblow (0 matching, Gjenson, 
Cecka, and T erasaki l () have nmed that tacrolimus-based im-
munosuppression improved cadaver kidney graft survival for 
more than any degree of matching, including perfect com-
patibiliry. With tacrolimus, the projected half-life of cadaver 
kidneys was (Wice that achievable with any previously available 
immunosuppressive regimen, including those based on cyclo-
sporine (14 versus 7 years). These findings were consistem 
with those in single-center 'OH and multicenter liver transplanta-
tion trials.H',X!.11 I The inescapable conclusion is that more ef-
fcctive immunosuppressive therapy rather than refinements in 
[issue matching and organ sharing will be rhe primary method 
or improving the results of whole organ transplantation. 
Cross Matching 
Allotranspla ntation 
None of .he iml11unosuppressive measures available today can 
prevent iml11ediate destruction or kidneys and other kinds of or-
gan grar.s in what has been called hyperacute rejection. This 
<':ol11plicllion was first seen widl the transplantation of kidneys 
frol11 AI\O-incompatible donors when they were placed in re-
'1(..1,. 27, -11.1.,1, '} I. 11111. ffF~K 
cipienrs wirh antidonor isoagglutinins. 74 After the description 
by Terasaki, Marchioro, and Stanl,,),1 of hyperacute kidney re-
jection by a recipienr with antidonor Iymphocytotoxic antibod-
ies, Kissmeyer-Nielsen et al;17 and othersH7 ,11l7,llc, confirmed the 
association of hyperacute rejection with these antigraft anti-
bodies. Although hyperacute rejection can usually be avoided 
with the lymphocytotoxic crossmatch originally recommended 
by Terasaki. Marchioro, and Stanl,IO,1 the precise pathogenesis 
of such rejection remains poorly understood more than 25 years 
after its recognition as an innate (primitive) immune reaction 
caused by complement activation and inflammatory media-
tors.78.87 Understanding and preventing this reaction is believed 
to be the key to successful xenorransplantation. % 
Xenotransplantation 
When organs are transplanted from a significantly disparate 
species, the first immunologic hurdle is that of preformed 
xenospeciflc antibodies and complement activation that quickly 
devascularize the graft by the same mechanisms as in ABO-
incompatible and presensitized allograft recipients.96 Although 
liver allografts and xenografts are resistant to such humoral (hy-
peracure) rejecrion,96 human liver xenotransplantation using 
chimpanzee donors76 was unsuccessful three rimes between 1966 
and 1973 with deaths after 0, 9, and 14 days.77 Two additional 
hepatic xenotransplantations were a[[empted in June 1992 and 
January 1993 with rhe phylogenetically more distant baboon 
donor. The recipiems survived for 70 and 26 days.83.96 The 
grafts did not funcrion normally, but neither antibody nor cell-
mediated rejection could be definitively indicted as responsible. 
Nevertheless, there was indirect evidence thar there had been 
a storm of inflammatory mediators, triggered by preformed 
xenospecific antibodies (principally IgM) and complement ac-
tivation. The failures were similar to those that had occurred af-
rer clinical chimpanzee61 and baboon renal rransplantation88 a 
third of a century ago and the more recent Baby Fae heart crans-
plamarion.6 A new generation of complement inhibitors3 or the 
much-publicized creation of transgenic animal donors whose 
organs contain transfected human complement regulatory 
genes4pKff~ may provide rhe missing piece in the treatment puz-
zle. No(Withstanding such hopes, the practical objecdve of clin-
ical xenorransplantation remains elusive, even with the use of 
closely related species. 
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